ArticleJournal of biosciences2022
Expression patterns of miR-34a, miR-125b, miR-221 and antioxidant gene NRF2 in plasma samples of patients with atherosclerosis.
Article in Journal of biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- Assessment of the effectiveness of serum-infrared spectroscopy in conjunction with multivariate analysis methods for atherosclerosis diagnosis.Scientific reports · 2026Article
- Epigenetic isoforms (DNMT3A/3B and HDAC3/7) potential predictors of endothelial dysfunction and subclinical atherosclerosis.Molecular biology reports · 2025Review
- Alteration in epigenetic profile in subclinical atherosclerosis and in high uric acid.Scientific reports · 2025Article
- The role of NRF2 function and regulation in atherosclerosis: an update.Molecular and cellular biochemistry · 2025Review
- Role of circulating microRNAs in tetralogy of Fallot.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- A comparison of the expression patterns and diagnostic capability of the ncRNAs NEAT1 and miR-34a in non-obstructive azoospermia and severe oligospermia.Human genomics · 2025Article
- Expression Analysis ofInternational journal of molecular and cellular medicine · 2025Article
- Paediatrics congenital heart disease is associated with plasma miRNAs.Pediatric research · 2024Article
- A cross-sectional study comparing the expression of DNA repair molecules in subjects with and without atherosclerotic plaques.Molecular biology reports · 2024Article
- Coronary artery disease patient-derived iPSC-hepatocytes have distinct miRNA profile that may alter lipid metabolism.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is one of the main reasons of cardiovascular diseases, the most common cause of death in the world. NRF2 is a critical transcriptional factor that regulates oxidative stress response and contributes to the pathogenesis of atherosclerosis. This study aims to compare the expression levels of miR-34a, miR-125b, miR- 221 and NRF2 in blood samples of patients with atherosclerosis and of controls to find a novel link between microRNAs, oxidative stress and atherosclerosis. miR-34a, miR-125b, miR-221 and NRF2 relative expressions were analysed in 26 atherosclerosis patients and 25 healthy controls by q-RT-PCR assay. The receiver operating characteristic curve (ROC) was used to assess the diagnostic values of miR-34a, miR-125b, miR-221 and NRF2 by comparing the area under the curves (AUC) to differentiate between atherosclerosis and control samples. miR-34a and NRF2 were significantly upregulated, whereas miR-125b and miR-221 were significantly downregulated in patients compared with healthy controls. The ROC curves suggested high diagnostic value of miR-221 (AUC: 0.7477), miR-125b (AUC: 0.8523) and NRF2 (AUC: 0.838) for detection of atherosclerosis. Our results suggest that circulating miR-34a, miR-125b and miR-221 levels can be used as novel biomarkers for detection of atherosclerosis by targeting NRF2.
Indexed as
Identifiers
34951407W4200300205What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.